Status:

COMPLETED

A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Cytomegalovirus Retinitis

HIV Infections

Eligibility:

All Genders

3+ years

Phase:

PHASE3

Brief Summary

To determine the safety and effectiveness of intravenous ganciclovir (also known as DHPG) in the treatment of sight-threatening cytomegalovirus (CMV) retinitis in patients with AIDS. CMV retinitis is ...

Detailed Description

CMV retinitis is a severe vision-threatening viral infection of the retina of the eye. It occurs in patients whose immune function has been impaired and is the most common cause of blindness in patien...

Eligibility Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia.
  • Topical ophthalmics.
  • Topical acyclovir.

Concurrent Treatment:

Allowed:

  • Hemodialysis for patients with renal impairment.

Patients must have:

  • Diagnosis of AIDS and immediately sight-threatening cytomegalovirus retinitis.

Prior Medication:

Allowed:

  • Zidovudine.
  • Prior therapy for retinitis.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Non-immediately sight-threatening cytomegalovirus retinitis.

Concurrent Medication:

Excluded:

  • Systemic investigational agents such as antimetabolites, alkylating agents, nucleoside analogs, acyclovir sodium (Zovirax).
  • Interferon.
  • Cytokines.
  • Foscarnet (non-nucleoside pyrophosphate analog).
  • Ganciclovir may be withheld for up to 21 days for an acute course with an investigational or toxic therapy or oral / IV acyclovir.

Patients with the following are excluded:

  • Non-immediately sight-threatening cytomegalovirus retinitis.

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

End Date :

August 1 2007

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00000698

End Date

August 1 2007

Last Update

September 30 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Natl Inst of Allergy & Infect Dis / Cln Ctr

Bethesda, Maryland, United States, 20892

A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis | DecenTrialz